TIDES USA 2026
5.11 – 5.14 | Boston, MA, USA
Latest Events & Articles
TIDES USA 2026
-
ASGCT Annual Meeting 2026
5.11 – 5.15 | Boston, MA, USA
-
The 3rd CRISPR MEDiCiNE Conference
4.14 – 4.16 | Copenhagen, Denmark
-
11th Annual OPT Congress
3.18 – 3.19 | Boston, MA, USA
-
RNA Leader Europe 2026
3.17 – 3.19 | Austria Center, Vienna, Austria
-
10th Annual RNA Symposium
3.06 – 3.07 | University of Michigan, MI, USA
-
Biotech Showcase 2026
1.12 – 1.14 | San Francisco, CA, USA
-
13th International mRNA Health Conference
11.11 – 11.13 | Berlin, Germany
-
TIDES Europe 2025
11.11 – 11.13 | Congress Center Basel, Basel, Switzerland
-
OTS 2025 Budapest
10.19 – 10.22 | Budapest, Hungary
-
N1C Annual Meeting 2025
10.18 | Budapest, Hungary
-
2025 RiboClub Annual Meeting
9.21 – 9.25 | Hôtel Chéribourg, Magog, Quebec, Canada
-
2nd Annual Meeting AMM ASCENT
9.16 – 9.18 | Coronado, CA, USA
Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support of SiranBio’s Dual-Target siRNA Program
Introduction Singapore, 5 May 2026: Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end...
-
Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw Materials
Introduction In Singapore, January 12, 2026; Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use in mRNA...
-
Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform
Introduction SINGAPORE (July 10th, 2025) – Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001, a...
-
Hongene Launches Operations at its New mRNA CDMO GMP Facility
Hongene launches operations at its new mRNA CDMO GMP facility, ensuring efficient, high-quality production of mRNA therapeutics and vaccines. The new facility consists of more than 30,000 sq. ft. of...
-
Hongene Partners with n-Lorem to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients
SAN DIEGO, Calif., April 24, 2024 (BUSINESS WIRE), Hongene Biotech Corporation, a global specialist in nucleic acid raw material supply and CDMO services, and n-Lorem, a nonprofit foundation formed a new partnership to support...
-
Deepening Cooperation in the Oligo Therapeutics Field: Hongene Biotech and Syensqo Sign Strategic Cooperation Agreement
NEWS Recently, at Hongene Biotech's high-tech GMP facility, Hongene Biotech and Syensqo officially signed a strategic cooperation framework agreement. This milestone event signifies that both parties will engage in deeper...
-
Hongene Biotech and ReciBioPharm Announce Strategic Collaboration in Gene Editing Field
NEWS On September 9, 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) service provider, and Hongene Biotech, a leading supplier in the nucleic acid raw materials field, announced...
Breaking Through Synthesis Challenges: Hongene Accelerates Clinical Translation of Dual-Targeting Oligonucleotide Drugs!
In recent years, dual-targeting oligonucleotide drugs have become one of the hottest fields in the global pharmaceutical industry due to their advantages of synergistic effects and avoiding combination therapy. Despite...
-
Ushering in a New Era of Lipid Management – Hongene Empowers Oligo Theraputics to Expand into Metabolic Diseases
Hypercholesterolemia is one of the most common chronic metabolic disorders. Its core characteristic is abnormally elevated levels of "bad cholesterol," or low-density lipoprotein cholesterol (LDL-C), which can form atherosclerotic plaques...
-
Enzymatic Ligation Synthesis Technology Application Case Study (Part 2): High-Fidelity sgRNA Synthesis
Introduction The widespread application of CRISPR-Cas technology in the gene editing field is driving rapid growth in the demand for sgRNA synthesis. However, the traditional SPOS (Solid-Phase Oligonucleotide Synthesis) method...
-
Case Study on the Application of Enzymatic Ligation Synthesis Technology (Part 1): High-Purity Synthesis of Bivalent siRNA
Introduction siRNA, as a type of RNA interference (RNAi) technology, has demonstrated significant value and potential in the fields of gene silencing and targeted therapy. During the development of siRNA...
-
Innovative Improvements in P(V) Oligonucleotide Synthesis Platform, Empowering Oligonucleotide Drug Development!
Introduction December 9, 2024 – A research team led by Professor Phil S. Baran from Scripps Research in the United States, in collaboration with researchers from Elsie Biotechnologies and Hongene...
-
Analysis of Core Materials and Process Strategies for Nucleic Acid Drugs
Introduction Nucleic acid drugs, including small nucleic acids and mRNA drugs, represent a rapidly growing segment within the biopharmaceutical field. With continuous technological iterations, particularly innovations in nucleic acid chemical...
Chemoenzymatic ligation comes of age: A present-day solution for scalable manufacturing for siRNA and sgRNA drugs
As the market demand for RNA therapeutics such as siRNA and sgRNA is anticipated to grow substantially over the next decade, there is a need for scalable, cost-effective, and sustainable...
-
The Evolving Landscape of Oligonuecleotide Manufacturing-Meeting Future Demand with Ligation Technologies
As several siRNA assets indicated for treating diseases associated with cardiovascular targets advance toward potential approval, the market demand for high-quality oligonucleotides is anticipated to grow substantially over the next...
